We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

35 hedge funds and large institutions have $13.1M invested in Axsome Therapeutics in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

27% more capital invested

Capital invested by funds: $10.4M → $13.1M (+$2.75M)

0.64% less ownership

Funds ownership: 16.61% → 15.97% (-0.64%)

3% less funds holding

Funds holding: 36 → 35 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

62% less call options, than puts

Call options by funds: $55K | Put options by funds: $145K

Holders
35
Holders Change
-1
Holders Change %
-2.78%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
8
Reduced
6
Closed
6
Calls
$55K
Puts
$145K
Net Calls
-$90K
Net Calls Change
-$126K

Top Buyers

1
ACM
Alethea Capital Management
Washington
+$478K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$145K
3
VF
Virtu Financial
New York
+$57.7K
4
Citadel Advisors
Citadel Advisors
Florida
+$48.3K
5
Wells Fargo
Wells Fargo
California
+$31K

Top Sellers

1
JP Morgan Chase
JP Morgan Chase
New York
-$306K
2
RA
Royce & Associates
New York
-$209K
3
SM
Sabby Management
Florida
-$199K
4
ARTA
A.R.T. Advisors
New York
-$117K
5
Group One Trading
Group One Trading
Illinois
-$91K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$29K – – –
SSB
27
Sandy Spring Bank
Maryland
$28K – – –
LTFS
28
Ladenburg Thalmann Financial Services
Florida
$12K – – –
IGGA
29
Iron Gate Global Advisors
Utah
$9K +$8.36K +2,697 New
ML
30
McAdam LLC
Pennsylvania
$6K +$6.2K +2,000 New
MAM
31
Meeder Asset Management
Ohio
$3.96K +$133 +43 +4%
RFA
32
Reilly Financial Advisors
California
$3K -$9.3K -3,000 -75%
TRCT
33
Tower Research Capital (TRC)
New York
$3K -$5.08K -1,638 -61%
UBS Group
34
UBS Group
Switzerland
$1K +$865 +279 New
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$10 – – –
SM
36
Sabby Management
Florida
– -$199K -81,159 Closed
DTL
37
Dynamic Technology Lab
Singapore
– -$65K -26,478 Closed
TSS
38
Two Sigma Securities
New York
– -$49K -20,126 Closed
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
– -$53.7K -17,318 Closed
Balyasny Asset Management
40
Balyasny Asset Management
Illinois
– -$34K -14,050 Closed
1
2

AXSM Hedge Fund Activity: Q2 2018 in Review

35 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2018, worth a combined $13.1M — up 27% from $10.4M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of AXSM and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 8 added.

The largest buyer was Alethea Capital Management, adding an estimated $478K. The largest seller was JP Morgan Chase, cutting an estimated $306K.

  • 35 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2018, down from 36 in Q1 2018.
  • Funds reported $13.1M of Axsome Therapeutics stock for Q2 2018, up 27% quarter-over-quarter.
  • 5 funds opened new Axsome Therapeutics positions in Q2 2018 and 6 closed out, a net change of -1 holder.
  • The largest Axsome Therapeutics buyer in Q2 2018 was Alethea Capital Management, an estimated $478K added.
  • The largest Axsome Therapeutics seller in Q2 2018 was JP Morgan Chase, an estimated $306K sold.

Based on aggregated 13F filings for Q2 2018.